The Human pancreatic carcinoma cell line KP-1N and its clone KP-1NL which has a high rate of liver metastasis were established. Ki-ras DNA point mutation on the codon 12 was found. The growth of KP-1N was stimulated by a physiological range of concentration (10-11–10-10 M) of cholecystokinin and the increase was inhibited by the addition of a cholecystokinin receptor antagonist (CR 1505). Daily injections of CR 1505 (35 mg/kg) diminished the number of tumor colonics in the liver that were formed after an intrasplenic injection of the highly liver metastatic KP-1NL cells. These results suggest that cholecystokinin antagonists may be useful as growth inhibitors for some pancreatic cancer.
CCK CR 1505 pancreatic cancer cell line
This is a preview of subscription content, log in to check access.
Ohyanagi H, Okumura S, Yamamoto Y, et al: Epidemiological study on pancreatic cancer. Jpn J Cancer Chemother 1985;12: 189–199. (in Japanese)Google Scholar
Ikeda Y, Ezaki M, Hayashi I, et al: Establishment and Characterization of Human Pancreatic Cancer Cell Lines in Tissue Culture and in Nude Mice. Jpn J Cancer Res 1990;81:987–993.PubMedGoogle Scholar
Townsend CM, Singh P, Thompson JC: Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas. Gastroenterology 1986;91:1002–1006.PubMedGoogle Scholar
Frazier ML, Pathak S, Wang Z-W, et al: Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3. Pancreas 1990;5:8–16.PubMedCrossRefGoogle Scholar
Smith JP, Mohesky C, Barrett B, et al: CCK stimulates growth of human pancreatic cancer [Abstract]. Dig Dis Sci 1986;31: 1150.Google Scholar
Douglas BR, Wouterson RA, Jansen JBMJ, et al: Influence of cholecystokinin receptor antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas. Gastroenterology 1989;96:462–469.PubMedGoogle Scholar
Setnikar I, Bani M, Cereda R, et al: Anticholecystokinin activities of loxiglumide. Arzneim Rorsch 1987;37:1168–1171.Google Scholar
Grunewald K, Lyons J, Frohlich A, et al: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037–1041.PubMedCrossRefGoogle Scholar
Niederau M, Niederay C, Strohmeyer G, et al: Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo. Am J Physiol 1989;256:G150–157.PubMedGoogle Scholar
Smith JP, Kramer ST, Solomon TE: CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium. Regul Pept 1991;32:341–349.PubMedCrossRefGoogle Scholar
Tada M, Omata M, Ohto M: Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 1991;100:233–238.PubMedGoogle Scholar
Holland E, Trocheris De St.-Front V, Lowet-Hermitte P, et al: Differentiation features of human pancreatic tumor cells maintained in nude mice and in culture: immunocytochemical and ultrastructural studies. Int J Cancer 1984;34:177–185.CrossRefGoogle Scholar